<DOC>
	<DOCNO>NCT02029313</DOCNO>
	<brief_summary>The Purpose A center , Randomized , Open label , single dose , Placebo-controlled , 2-Treatment , 2-Way , 2-Period Crossover Study Compare Safety Pharmacokinetic Characteristics MKT-N2 ( Montelukast ) Singulair® ( montelukast sodium ) tablet 10mg Healthy Male Korean Subjects</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Characteristics MKT-N2 ( Montelukast ) Singulair® ( Montelukast Sodium ) Treat Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Healthy Korean Male over20 , 45 year old 55kg weight , IBW +20 % range male Males get clinically significant liver , pancreas , kidney , nervous system , respiratory system , endocrine system , blood cancer , mental illness , cardiovascular , urinary tract disease , history correspond Males gotten history gastrointestinal disease Males get history hypersensitivity montelukast reaction drug ( aspirin , antibiotic )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>